You are here: Industry Insights > CTP-543

News List

Concert Pharmaceuticals announces plans for CTP-543 phase 3 trials in alopecia areata pharmaceutical-business-review
April 06, 2020
Concert Pharmaceuticals announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.
Concert Pharmaceuticals Successfully Completes CTP-543 Open Label Trial americanpharmaceuticalreview
December 24, 2019
Concert Pharmaceuticals has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata.
Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata pharmafocusasia
March 07, 2019
Concert Pharmaceuticals, Inc. today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.